Cargando…

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients

INTRODUCTION: Secondary hyperparathyroidism (SHPT) and vitamin D deficiency are common at kidney transplantation and are associated with some early and late complications. This study was designed to evaluate whether paricalcitol was more effective than nutritional vitamin D for controlling SHPT in d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cruzado, Josep M., Lauzurica, Ricardo, Pascual, Julio, Marcen, Roberto, Moreso, Francesc, Gutierrez-Dalmau, Alex, Andrés, Amado, Hernández, Domingo, Torres, Armando, Beneyto, Maria Isabel, Melilli, Edoardo, Manonelles, Anna, Arias, Manuel, Praga, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762965/ https://www.ncbi.nlm.nih.gov/pubmed/29340322 http://dx.doi.org/10.1016/j.ekir.2017.08.016

Ejemplares similares

Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis
por: Franchi, Matteo, et al.
Publicado: (2023)

Antibiotic Treatment Versus No Treatment for Asymptomatic Bacteriuria in Kidney Transplant Recipients: A Multicenter Randomized Trial
por: Sabé, Núria, et al.
Publicado: (2019)

The Presence of Urinary Renal Progenitor Cells in Stable Kidney Transplant Recipients Anticipates Allograft Deterioration
por: Manonelles, Anna, et al.
Publicado: (2018)

Outcome of Kidney Transplants from Viremic and Non-Viremic Hepatitis C Virus Positive Donors into Negative Recipients: Results of the Spanish Registry
por: Franco, Antonio, et al.
Publicado: (2023)

Pre-Transplant Donor-Specific T-Cell Alloreactivity Is Strongly Associated with Early Acute Cellular Rejection in Kidney Transplant Recipients Not Receiving T-Cell Depleting Induction Therapy
por: Crespo, Elena, et al.
Publicado: (2015)

Impact of immunosuppressive therapy on arterial stiffness in kidney transplantation: are all treatments the same?
por: Melilli, Edoardo, et al.
Publicado: (2018)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Effects of body weight variation in obese kidney recipients: a retrospective cohort study
por: Montero, Nuria, et al.
Publicado: (2019)

Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome
por: Meneghini, Maria, et al.
Publicado: (2018)

Looking for the needle in the kidney transplantation haystack
por: Cruzado, Josep M., et al.
Publicado: (2017)

Calcifediol Cornerstone of the Vitamin D Endocrine System
por: Quesada-Gomez, Jose Manuel, et al.
Publicado: (2023)

Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney Transplantation
por: Meneghini, Maria, et al.
Publicado: (2021)

Cholecalciferol or Calcifediol in the Management of Vitamin D Deficiency
por: Sosa Henríquez, Manuel, et al.
Publicado: (2020)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Calcifediol: Mechanisms of Action
por: Donati, Simone, et al.
Publicado: (2023)

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
por: Izquierdo, María Jesús, et al.
Publicado: (2012)

Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol
por: Hansen, Ditte, et al.
Publicado: (2009)

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperparathyroidism in a haemodialysis patient
por: Cozzolino, Mario, et al.
Publicado: (2008)

Risk Factors and Outcomes of Acute Graft Pyelonephritis with Bacteremia Due to Multidrug-Resistant Gram-Negative Bacilli among Kidney Transplant Recipients
por: Sabé, Núria, et al.
Publicado: (2022)

Impact of HLA Mismatching on Early Subclinical Inflammation in Low-Immunological-Risk Kidney Transplant Recipients
por: Hernández, Domingo, et al.
Publicado: (2021)

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient
por: Melilli, Edoardo, et al.
Publicado: (2021)

Bioavailability of once‐daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study
por: Fernandez Rivera, Constantino, et al.
Publicado: (2021)

Effectiveness and Safety of Ultrasound-Guided Local Paricalcitol Injection in Treating Secondary Hyperparathyroidism in ESRD: A Retrospective Study
por: Xie, Shuqin, et al.
Publicado: (2022)

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Cardoso, Marilia Mastrocolla de Almeida, et al.
Publicado: (2022)

Rapid Nontranscriptional Effects of Calcifediol and Calcitriol
por: Donati, Simone, et al.
Publicado: (2022)

Calcifediol for Use in Treatment of Respiratory Disease
por: Entrenas-Castillo, Marta, et al.
Publicado: (2022)

Calcifediol: Why, When, How Much?
por: Donati, Simone, et al.
Publicado: (2023)

Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
por: Germain, Michael J., et al.
Publicado: (2022)

Vitamin D Endocrine System and COVID-19: Treatment with Calcifediol
por: Quesada-Gomez, Jose Manuel, et al.
Publicado: (2022)

Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients
por: Pihlstrøm, Hege Kampen, et al.
Publicado: (2020)

Immunosuppression minimization in kidney transplant recipients hospitalized for COVID-19
por: Anton Pampols, Paula, et al.
Publicado: (2021)

Effect of kidney replacement therapy modality after first kidney graft failure on second kidney transplantation outcomes
por: Couceiro, Carlos, et al.
Publicado: (2022)

Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2013)

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis
por: Zhang, Zhuolin, et al.
Publicado: (2021)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

Hypovitaminosis D: Is It Time to Consider the Use of Calcifediol?
por: Cesareo, Roberto, et al.
Publicado: (2019)

Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA
por: Sharma, Amit, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o3p0fkkrpd4mbpmuc72johu5ts